{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["39(8)"],"submitter":["Wang S"],"pubmed_abstract":["The rapidly spreading Omicron variant is highly resistant to vaccines, convalescent sera, and neutralizing antibodies (nAbs), highlighting the urgent need for potent therapeutic nAbs. Here, a panel of human nAbs from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent patients show diverse neutralization against Omicron, of which XMA01 and XMA04 maintain nanomolar affinities and excellent neutralization (half maximal inhibitory concentration [IC50]: ∼20 ng/mL). nAb XMA09 shows weak but unattenuated neutralization against all variants of concern (VOCs) as well as SARS-CoV. Structural analysis reveals that the above three antibodies could synergistically bind to the receptor-binding domains (RBDs) of both wild-type and Omicron spikes and defines the critical determinant"],"journal":["Cell reports"],"pagination":["110862"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9080080"],"repository":["biostudies-literature"],"pubmed_title":["Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron."],"pmcid":["PMC9080080"],"pubmed_authors":["Tang Z","Zheng Z","Liu L","Zhang J","Yuan Q","Yuan L","Zheng Q","Yu H","Cheng T","Guan Y","Zhang T","Huang Y","Li S","Li T","Chen Z","Wang S","Zhang Y","Ying D","Xia N","Chen X","Liu C","Sun H","Wang Y","Xiong H"],"additional_accession":[]},"is_claimable":false,"name":"Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron.","description":"The rapidly spreading Omicron variant is highly resistant to vaccines, convalescent sera, and neutralizing antibodies (nAbs), highlighting the urgent need for potent therapeutic nAbs. Here, a panel of human nAbs from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent patients show diverse neutralization against Omicron, of which XMA01 and XMA04 maintain nanomolar affinities and excellent neutralization (half maximal inhibitory concentration [IC50]: ∼20 ng/mL). nAb XMA09 shows weak but unattenuated neutralization against all variants of concern (VOCs) as well as SARS-CoV. Structural analysis reveals that the above three antibodies could synergistically bind to the receptor-binding domains (RBDs) of both wild-type and Omicron spikes and defines the critical determinant","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-05-31T05:03:59.828Z","creation":"2025-02-19T01:54:56.63Z"},"accession":"S-EPMC9080080","cross_references":{"pubmed":["35594869"],"doi":["10.1016/j.celrep.2022.110862"]}}